UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

Journal of hematology and oncology, 2021-02, Vol.14 (1), p.37-37, Article 37

2021

Volltextzugriff (PDF)

Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling

Journal of nanobiotechnology, 2023-02, Vol.21 (1), p.45-25, Article 45

2023

Volltextzugriff (PDF)

Targeting Autophagy Augments In Vitro and In Vivo Antimyeloma Activity of DNA-Damaging Chemotherapy

Clinical cancer research, 2011-05, Vol.17 (10), p.3248-3258

2011

Volltextzugriff (PDF)

Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China

BMC cancer, 2023-10, Vol.23 (1), p.1-930, Article 930

2023

Volltextzugriff (PDF)

Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis

Cell transplantation, 2020-01, Vol.29, p.963689720975397-963689720975397

2020

Volltextzugriff (PDF)

PB2589: EFFICACY AND SAFETY OF ABCD IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS WITH HEMATOLOGIC DISEASES

HemaSphere, 2023-08, Vol.7 (S3), p.e1933108-n/a

2023

Volltextzugriff (PDF)

Kill two birds with one stone: Engineered exosome-mediated delivery of cholesterol modified YY1-siRNA enhances chemoradiotherapy sensitivity of glioblastoma

Frontiers in pharmacology, 2022-08, Vol.13, p.975291-975291

2022

Volltextzugriff (PDF)

Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities

Frontiers in oncology, 2022-03, Vol.12, p.805702-805702

2022

Volltextzugriff (PDF)

A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis

Frontiers in oncology, 2023-03, Vol.13, p.1104425-1104425

2023

Volltextzugriff (PDF)

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens

Frontiers in oncology, 2022-09, Vol.12, p.938550-938550

2022

Volltextzugriff (PDF)

Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells

Molecular cancer therapeutics, 2008-08, Vol.7 (8), p.2298-2307

2008

Volltextzugriff (PDF)

Anti-cancer drug discovery: update and comparisons in yeast, Drosophila, and zebrafish

Current molecular pharmacology, 2015-01, Vol.7 (1), p.44-51

2015

Volltextzugriff (PDF)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

Frontiers in oncology, 2021-11, Vol.11, p.750323-750323

2021

Volltextzugriff (PDF)

The R2‐ISS in a Multicenter Cohort of Chinese Patients With Newly Diagnosed Multiple Myeloma

HemaSphere, 2023-04, Vol.7 (4), p.e857-n/a

2023

Volltextzugriff (PDF)

The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma

Blood cancer journal (New York), 2022-09, Vol.12 (9), p.1-4, Article 134

2022

Volltextzugriff (PDF)

Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials

Journal of immunology research, 2018-01, Vol.2018 (2018), p.1-20

2018

Volltextzugriff (PDF)

P974: INTERIM ANALYSIS OF THE LAUNCH STUDY‐A MULTICENTER, OPEN‐LABEL STUDY OF SELINEXOR, DEXAMETHASONE PLUS CHEMOTHERAPY DRUGS IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e15485de-n/a

2023

Volltextzugriff (PDF)

P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN‐BASED CONDITIONING REGIMEN FOR ALLOGENEIC‐HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS

HemaSphere, 2023-08, Vol.7 (S3), p.e352651c-n/a

2023

Volltextzugriff (PDF)

Cheliensisin A Inhibits EGF-Induced Cell Transformation with Stabilization of p53 Protein Via a Hydrogen Peroxide/Chk1-Dependent Axis

Cancer prevention research (Philadelphia, Pa.), 2013-09, Vol.6 (9), p.949-958

2013

Volltextzugriff (PDF)

Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies

Cancer cell, 2020-10, Vol.38 (4), p.551-566.e11

2020

Volltextzugriff (PDF)

Momelotinib for the treatment of myelofibrosis

Expert opinion on pharmacotherapy, 2019-11, Vol.20 (16), p.1943-1951

2019

Volltextzugriff (PDF)

MEG3 modulates TIGIT expression and CD4 + T cell activation through absorbing miR-23a

Molecular and cellular biochemistry, 2019-04, Vol.454 (1-2), p.67-76

2019

Volltextzugriff (PDF)

Interim Results of the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.4763-4763

2023

Volltextzugriff (PDF)

Treatment options for older unfit patients with acute myeloid leukemia

Future oncology (London, England), 2021-03, Vol.17 (7), p.837-851

2021

Volltextzugriff (PDF)

A new chemotherapy‐free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study

American journal of hematology, 2024-06, Vol.99 (6), p.1177-1179

2024

Volltextzugriff (PDF)

1 – 25 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(100)

Publikationsform

Sprache

Englisch
(106)
Chinesisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling

Targeting Autophagy Augments In Vitro and In Vivo Antimyeloma Activity of DNA-Damaging Chemotherapy

Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China

Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis

PB2589: EFFICACY AND SAFETY OF ABCD IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS WITH HEMATOLOGIC DISEASES

Kill two birds with one stone: Engineered exosome-mediated delivery of cholesterol modified YY1-siRNA enhances chemoradiotherapy sensitivity of glioblastoma

Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities

A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens

Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells

Anti-cancer drug discovery: update and comparisons in yeast, Drosophila, and zebrafish

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

The R2‐ISS in a Multicenter Cohort of Chinese Patients With Newly Diagnosed Multiple Myeloma

The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma

Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials

P974: INTERIM ANALYSIS OF THE LAUNCH STUDY‐A MULTICENTER, OPEN‐LABEL STUDY OF SELINEXOR, DEXAMETHASONE PLUS CHEMOTHERAPY DRUGS IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA

P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN‐BASED CONDITIONING REGIMEN FOR ALLOGENEIC‐HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS

Cheliensisin A Inhibits EGF-Induced Cell Transformation with Stabilization of p53 Protein Via a Hydrogen Peroxide/Chk1-Dependent Axis

Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies

Momelotinib for the treatment of myelofibrosis

MEG3 modulates TIGIT expression and CD4 + T cell activation through absorbing miR-23a

Interim Results of the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma

Treatment options for older unfit patients with acute myeloid leukemia

A new chemotherapy‐free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study

Suchergebnisse filtern